Antibodies to the Iron Uptake ABC Transporter Lipoproteins PiaA and PiuA Promote Opsonophagocytosis of Streptococcus pneumoniae
Open Access
- 1 October 2005
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 73 (10) , 6852-6859
- https://doi.org/10.1128/iai.73.10.6852-6859.2005
Abstract
PiaA and PiuA are the lipoprotein components of the Pia and Piu Streptococcus pneumoniae iron uptake ABC transporters and are required for full virulence in mouse models of infection. Active or passive vaccination with recombinant PiuA and PiaA protects mice against invasive S. pneumoniae disease. In this study we have analyzed the antibody responses and mechanism of protection induced by PiuA and PiaA in more detail. For both proteins, two booster vaccinations induced stronger antibody responses in mice than a single or no booster vaccinations, and 5 μg of protein induced similar levels of antibody responses as 20 μg. Immunoglobulin G (IgG) subclass-specific enzyme-linked immunosorbent assays demonstrated that the antibody response to PiuA and PiaA was predominantly IgG1, with induction of only low levels of IgG2a. Anti-PiaA and anti-PiuA polyclonal rabbit antibodies bound to the surface of live S. pneumoniae when assessed by flow cytometry but did not inhibit growth of S. pneumoniae in cation-depleted medium or bacterial susceptibility to the iron-dependent antibiotic streptonigrin. However, anti-PiaA and anti-PiuA did increase complement-independent and -dependent opsonophagocytosis of different serotypes of S. pneumoniae by the human neutrophil cell line HL60. Hence, vaccination with PiaA and PiuA protects against S. pneumoniae infection by inducing antibodies that promote bacterial opsonophagocytosis rather than inhibiting iron transport.Keywords
This publication has 36 references indexed in Scilit:
- PiuA and PiaA, iron uptake lipoproteins ofStreptococcus pneumoniae, elicit serotype independent antibody responses following human pneumococcal septicaemiaFEMS Immunology & Medical Microbiology, 2005
- FcγRIIb Balances Efficient Pathogen Clearance and the Cytokine-mediated Consequences of SepsisThe Journal of Experimental Medicine, 2004
- A Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with and Those without HIV InfectionNew England Journal of Medicine, 2003
- Protective efficacy ofpspA(pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responsesFEMS Immunology & Medical Microbiology, 2003
- Characterization of Pit, a Streptococcus pneumoniae Iron Uptake ABC TransporterInfection and Immunity, 2002
- Intranasal Vaccination with Pneumococcal Surface Protein A and Interleukin-12 Augments Antibody-Mediated Opsonization and Protective Immunity againstStreptococcus pneumoniaeInfectionInfection and Immunity, 2001
- Use of a Whole Genome Approach To Identify Vaccine Molecules Affording Protection against Streptococcus pneumoniae InfectionInfection and Immunity, 2001
- Efficacy of a Pneumococcal Conjugate Vaccine against Acute Otitis MediaNew England Journal of Medicine, 2001
- The Putative Proteinase Maturation Protein A of Streptococcus pneumoniae Is a Conserved Surface Protein with Potential To Elicit Protective Immune ResponsesInfection and Immunity, 2000
- Immunization of Mice with Combinations of Pneumococcal Virulence Proteins Elicits Enhanced Protection against Challenge with Streptococcus pneumoniaeInfection and Immunity, 2000